Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort

This longitudinal retrospective study aims at describing the safety profile and the reasons for discontinuation of antimalarials in patients with systemic lupus erythematosus (SLE) and discoid lupus erythematosus (DLE), focusing on ocular toxicity. We analyzed the clinical data of 845 SLE and DLE patients; 59% of them were taking antimalarials: 1.4% chloroquine (CQ), 88.5% hydroxychloroquine (HCQ) and 10.1% both. The mean therapy duration was 82.5 ± 77.4 months. At least one side effect was reported by 19.4% of patients, leading to temporary or permanent withdrawal in 9.1% and 10.3% of cases, respectively; 19.3% of patients experienced side effects with HCQ and 8.6% with CQ. In 55.1% of cases, the adverse event was mild or moderate. Ophthalmological alterations were reported by 8.5% but were confirmed by the ophthalmological examination in 5.5% of cases. Retinal alterations were associated with age, disease duration and duration of the antimalarial therapy, but not to drug dose and comorbidities or lupus nephritis. This is the largest monocentric longitudinal study confirming the good safety profile of antimalarials in DLE and SLE patients. The main adverse events during the therapy were mild or moderate, but maculopathy—reported in a low percentage of patients—remains the main cause of treatment withdrawal.

[1]  Gerald. D. Levy,et al.  Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. , 1997, Arthritis and rheumatism.

[2]  M. V. Van Beek,et al.  Antimalarials , 2001, Dermatologic clinics.

[3]  P. Stas,et al.  Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine. , 2008, International journal of cardiology.

[4]  C. Alessandri,et al.  Biological therapies in rheumatic diseases. , 2013, La Clinica terapeutica.

[5]  Michael S. Lee.  Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy , 2011 .

[6]  G. Hughes,et al.  Treatment of systemic lupus erythematosus. , 2001, International immunopharmacology.

[7]  S. Kalia,et al.  New concepts in antimalarial use and mode of action in dermatology , 2007, Dermatologic therapy.

[8]  J. Piette,et al.  Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. , 2003, Arthritis and rheumatism.

[9]  M. Marmor,et al.  Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). , 2016, Ophthalmology.

[10]  M. Marmor,et al.  Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. , 2002, Ophthalmology.

[11]  M. Marmor,et al.  The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. , 2014, JAMA ophthalmology.

[12]  W. Louthrenoo,et al.  Ocular side effects of chloroquine in patients with rheumatoid arthritis, systemic lupus erythematosus and scleroderma. , 2007, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[13]  M. Petri,et al.  Fetal outcome of lupus pregnancy: a retrospective case-control study of the Hopkins Lupus Cohort. , 1993, The Journal of rheumatology.

[14]  R. Kandolf,et al.  Chloroquine cardiomyopathy – a review of the literature , 2013, Immunopharmacology and immunotoxicology.

[15]  M. Marmor,et al.  A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye , 2015, Clinical Reviews in Allergy & Immunology.

[16]  M. Marmor,et al.  Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus , 2010, Arthritis care & research.

[17]  Ş. Kobak,et al.  Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? A single center retrospective study , 2010, International journal of rheumatic diseases.

[18]  A. Gressard,et al.  Les effets cardiovasculaires liés à l'utilisation de la chloroquine , 2001 .

[19]  M. Lockshin,et al.  Lupus Pregnancy , 2003, Clinics in rheumatic diseases.

[20]  P. Tutor-Ureta,et al.  Los antimaláricos en las enfermedades sistémicas , 2005 .

[21]  A. Wozniacka,et al.  Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit , 2002, Lupus.

[22]  A. Voskuyl,et al.  Long-term evaluation of antimalarials in a Dutch SLE cohort: intolerance and other reasons for non-use. , 2014, Clinical and experimental rheumatology.

[23]  J. Esdaile,et al.  Discontinuation of antimalarial drugs in systemic lupus erythematosus. , 1999, The Journal of rheumatology.

[24]  D. Lacomis,et al.  42‐YEAR‐OLD MAN WITH DISCOID LUPUS AND PROGRESSIVE WEAKNESS , 2009, Brain pathology.

[25]  G. Hughes,et al.  Hydroxychloroquine, Dosage Parameters and Retinopathy , 1993, Lupus.

[26]  M. Marmor,et al.  Effect of disease stage on progression of hydroxychloroquine retinopathy. , 2014, JAMA ophthalmology.

[27]  Petros P Sfikakis,et al.  The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. , 2003, Ophthalmology.

[28]  E. B. Safawi,et al.  Abdominal wall reconstruction after resection of an enterocutaneous fistula with an island pedicled anterolateral thigh perforator flap. Case report. , 2013, La Clinica terapeutica.

[29]  C. Newton-Cheh,et al.  Case records of the Massachusetts General Hospital. Case 11-2011. A 47-year-old man with systemic lupus erythematosus and heart failure. , 2011, The New England journal of medicine.

[30]  D. Wendling,et al.  AB0453 Response to TOCILIZUMAB in Rheumatoid Arthritis is not Influenced by the Body Mass Index of the Patient , 2014 .

[31]  F. Medeiros,et al.  Retinal nerve fibre layer thickness measurements in patients using chloroquine , 2006, Clinical & experimental ophthalmology.

[32]  E. Morand,et al.  Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. , 1992, Annals of the rheumatic diseases.

[33]  Chih-Chuan Lin,et al.  Chronic Hydroxychloroquine Use Associated with QT Prolongation and Refractory Ventricular Arrhythmia , 2006, Clinical toxicology.

[34]  M. Vilar,et al.  Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. , 2005, Arthritis and rheumatism.

[35]  J. Ioannidis,et al.  EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics , 2007, Annals of the rheumatic diseases.

[36]  M. Suarez‐Almazor,et al.  Long term effectiveness of antimalarial drugs in rheumatic diseases , 1998, Annals of the rheumatic diseases.

[37]  I. Bruce,et al.  Treat-to-target in systemic lupus erythematosus: recommendations from an international task force , 2014, Annals of the rheumatic diseases.

[38]  A. Fawzi,et al.  Retinal toxicity found in a patient with systemic lupus erythematosus prior to 5 years of treatment with hydroxychloroquine. , 2014, Rheumatology.

[39]  M. Khamashta,et al.  Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review , 2008, Annals of the rheumatic diseases.

[40]  Carlo Uribe,et al.  Chloroquine cardiomyopathy: beyond ocular adverse effects , 2014, BMJ Case Reports.

[41]  D. Newsome,et al.  Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. , 1985, The Journal of rheumatology.

[42]  L. Magder,et al.  Hydroxychloroquine in lupus pregnancy. , 2006, Arthritis and rheumatism.

[43]  J. Pouchot,et al.  Adherence to treatment in systemic lupus erythematosus patients. , 2013, Best practice & research. Clinical rheumatology.